ICI-204,448
ICI-204,448 is a chemical compound that acts as a selective antagonist of the leukotriene D4 (LTD4) receptor. It is primarily used in scientific research to study the role of leukotrienes in various physiological and pathological processes.
Chemical Properties
ICI-204,448 is a member of the class of compounds known as quinolines. It has a molecular formula of C_20H_19N_3O_2 and a molecular weight of 333.39 g/mol. The compound is characterized by its high affinity and selectivity for the LTD4 receptor, making it a valuable tool in pharmacological studies.
Mechanism of Action
ICI-204,448 functions by competitively inhibiting the binding of leukotriene D4 to its receptor. Leukotrienes are inflammatory mediators derived from arachidonic acid through the lipoxygenase pathway. By blocking the LTD4 receptor, ICI-204,448 can modulate inflammatory responses, particularly in conditions such as asthma and allergic rhinitis.
Applications in Research
ICI-204,448 is widely used in preclinical studies to investigate the role of leukotrienes in various diseases. It has been instrumental in elucidating the mechanisms underlying inflammatory responses and has potential therapeutic implications for conditions characterized by excessive leukotriene activity.
Asthma
In asthma research, ICI-204,448 has been used to demonstrate the contribution of leukotrienes to bronchoconstriction and airway hyperresponsiveness. Studies have shown that blocking the LTD4 receptor can reduce the severity of asthma symptoms, highlighting the potential for leukotriene receptor antagonists in asthma management.
Allergic Rhinitis
ICI-204,448 has also been employed in studies of allergic rhinitis, where leukotrienes play a significant role in mediating nasal congestion and other symptoms. By inhibiting the LTD4 receptor, ICI-204,448 helps to clarify the pathways involved in allergic responses and supports the development of targeted therapies.
Safety and Toxicology
As with any pharmacological agent, the safety profile of ICI-204,448 is an important consideration. Preclinical studies have assessed its toxicity and potential side effects, providing valuable data for its use in research settings. However, detailed safety information specific to ICI-204,448 is limited and requires further investigation.
Conclusion
ICI-204,448 is a potent and selective LTD4 receptor antagonist with significant applications in the study of inflammatory diseases. Its ability to block leukotriene-mediated responses makes it a valuable tool in both basic and applied research, contributing to our understanding of conditions such as asthma and allergic rhinitis.
See Also
References
External Links
-
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD